| 000 | 01011nam a22002777a 4500 | ||
|---|---|---|---|
| 001 | 06217 | ||
| 003 | HDC | ||
| 007 | cr bn ---aaaaa | ||
| 008 | 210123b20052005xxu||||| |||| 00| 0 eng d | ||
| 020 | _a9781420070422 | ||
| 040 | _aHDC | ||
| 100 |
_aLazar, Max S. _eauthor _96542 |
||
| 245 | 0 |
_aActive Pharmaceutical Ingredients _c/ Max S. Lazar |
|
| 260 |
_aNew York: _bMarcel Dekker, _c2005 |
||
| 300 | _a1 online resource (16 pages) | ||
| 336 |
_atext _2rdacontent |
||
| 337 |
_acomputer _2rdamedia |
||
| 338 |
_aonline resource _2rdacarrier |
||
| 500 |
_aOriginally from: The pharmaceutical regulatory process, 2005 (pages 377-392) _aIncludes bibliographical references |
||
| 650 |
_aDrugs _xLaw and legislation _96544 |
||
| 650 |
_aPharmacy _xLaw and legislation _96543 |
||
| 856 | _zRequest full-text at [email protected] | ||
| 942 | _2lcc | ||
| 942 | _cCHAP | ||
| 942 | _kEBCH 004236 | ||
| 999 |
_c3541 _d3541 |
||